A Prospective, Observational Study on the Correlations Between Change in Lung Function and Change in Cough and Dyspnoea in Patients With Connective Tissue Disease-associated Progressive Fibrosing INTErstitial luNg diseaSE (CTD Associated PF-ILD) Treated With Nintedanib. The "INTENSE" Study
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases
- Focus Therapeutic Use
- Acronyms The INTENSE Study
- Sponsors Boehringer Ingelheim
Most Recent Events
- 10 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2023 Planned End Date changed from 30 Nov 2026 to 30 Dec 2026.
- 23 Jan 2023 Planned primary completion date changed from 30 Nov 2026 to 30 Dec 2026.